<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Steven Martens</style></author><author><style face="normal" font="default" size="100%">Lize Cuypers</style></author><author><style face="normal" font="default" size="100%">Florian Bélik</style></author><author><style face="normal" font="default" size="100%">Pieter-Jan Briers</style></author><author><style face="normal" font="default" size="100%">Pieter-Jan Ceyssens</style></author><author><style face="normal" font="default" size="100%">Denis, Olivier</style></author><author><style face="normal" font="default" size="100%">Huang, Te-Din</style></author><author><style face="normal" font="default" size="100%">Koen Magerman</style></author><author><style face="normal" font="default" size="100%">Thomas Strypens</style></author><author><style face="normal" font="default" size="100%">Van den Abeele, Anne-Marie</style></author><author><style face="normal" font="default" size="100%">Stefanie Desmet</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Belgian National Antibiogram Committee</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Multicenter comparison of Etest, Vitek2 and BD Phoenix to broth microdilution for beta-lactam susceptibility testing of Streptococcus pneumonia.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">beta-Lactams</style></keyword><keyword><style  face="normal" font="default" size="100%">Disk Diffusion Antimicrobial Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Streptococcus pneumoniae</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">43</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;PURPOSE: &lt;/b&gt;To assess performance of Etest®, Vitek®2 and BD Phoenix™ to determine the susceptibility of Streptococcus pneumoniae strains to penicillin, ampicillin and cefotaxime.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Sixty unique S. pneumoniae challenge strains were selected to cover a wide range of penicillin, ampicillin and cefotaxime minimal inhibitory concentrations (MICs). Strains were analyzed in four different Belgian laboratories. Etest® benzylpenicillin (BEN), ampicillin/amoxicillin (AMP) and cefotaxime (CTA) (bioMérieux), Vitek®2 AST-ST03 (bioMérieux) and BD Phoenix™ SMIC/ID-11 testing were each performed in two different labs. Results were compared to Sensititre® broth microdilution (BMD) (Thermo Fisher Scientific) results. MIC results were interpreted using EUCAST non-meningitis breakpoints (v 13.0).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Essential agreement (EA) was ≥ 90% for all methods compared to BMD, except for Etest® BEN on Oxoid plate (58.3%), Etest® AMP (both on Oxoid (65.8%) and BD BBL plate (84.2%)). Categorical agreement (CA) for penicillin was only ≥ 90% for Vitek®2, for other methods CA ranged between 74 and 84%. CA for AMP was for all methods &amp;lt; 90% (range 75.8-88.3%) and CA for CTA was between 87 and 90% for all methods except for Etest on Oxoid plate (79.2%).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Our study indicates that Vitek®2 and BD Phoenix™ are reliable for providing accurate pneumococcal susceptibility results for BEN, AMP and CTA. Using Etest BEN or AMP on Oxoid plate carries a risk of underestimating the MIC and should be interpreted with caution, especially when the obtained MIC is 1 or 2 doubling dilutions below the S or R clinical breakpoint.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue></record></records></xml>